
Unpredictability in the industry and beyond is rife, but talent acquisition remains a key issue for Pharma and Life Sciences. …

The FDA has given its approval for the commercialisation of the first-ever generic versions of Eli Lilly’s Strattera (atomoxetine) for …

Roche, the supplier of Valium in Australia, had notified the Therapeutic Goods Administration (TGA) that it had discovered evidence of …

Novartis has revealed that increasing pressure on pricing in the US has impacted its second-quarter business, cutting into sales generated …

There were fears in Ireland that President Trump’s strong words to bring manufacturing back to the US would hurt the …

Scientists at The Scripps Research Institute (TSRI) have succeeded in reengineering vancomycin – a widely-used antibiotic – in order to …

Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership …

Glenmark Pharmaceuticals has revealed it has been awarded final approval by the FDA to market hypertension treatment nebivolol, a generic …

New research from the University of Leeds has called into question the prevalent practice of prescribing beta blockers for heart …

The FDA has announced it has approved Novartis’ Zykadia (ceritinib) as a first line treatment in the expanded indication of …

Gene-editing has been heralded as a wonder tool which could lead to huge advances in a wide range of treatment …
London, May 30, 2017 – Global Pricing Innovations (GPI), the pricing and intelligence experts for the life sciences industry and …

Ethiopian-born Tedros Adhanom Ghebreyesus has been announced as the Next Director General of the World Health Organization (WHO) after securing …

Bad Manufacturing Practices: Changing Markets examines China’s role in the antibiotics supply chain and the damaging pollution that results from …

Deregulation, faster access and cheaper drug prices very quickly became the rallying cry for the Trump administration in the life …

A company that assesses DNA is dealing with the repercussions of public outcry after a data protection lawyer highlighted a …

Among other things, it’s been a week characterised by safety failures as three of our most popular stories centred on …

Puma Biotechnology breast cancer drug that could be used to reduce the risk of disease recurrence has been boosted by …

As published in the special Market Access section of the latest issue of Pharmafocus, Liz Lewis, Chief Counsel & Compliance …

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …